272 related articles for article (PubMed ID: 32972803)
1. Second primary malignancies in multiple myeloma: A review.
Poh C; Keegan T; Rosenberg AS
Blood Rev; 2021 Mar; 46():100757. PubMed ID: 32972803
[TBL] [Abstract][Full Text] [Related]
2. Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
Musto P; Anderson KC; Attal M; Richardson PG; Badros A; Hou J; Comenzo R; Du J; Durie BGM; San Miguel J; Einsele H; Chen WM; Garderet L; Pietrantuono G; Hillengass J; Kyle RA; Moreau P; Lahuerta JJ; Landgren O; Ludwig H; Larocca A; Mahindra A; Cavo M; Mazumder A; McCarthy PL; Nouel A; Rajkumar SV; Reiman A; Riva E; Sezer O; Terpos E; Turesson I; Usmani S; Weiss BM; Palumbo A;
Ann Oncol; 2017 Feb; 28(2):228-245. PubMed ID: 27864218
[TBL] [Abstract][Full Text] [Related]
3. The risk of secondary primary malignancies after therapy for multiple myeloma.
Areethamsirikul N; Reece DE
Leuk Lymphoma; 2015; 56(11):3012-21. PubMed ID: 25947036
[TBL] [Abstract][Full Text] [Related]
4. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.
Rollison DE; Komrokji R; Lee JH; Hampras S; Fulp W; Fisher K; Baz R; Nishihori T; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Sullivan D; Alsina M; Dalton W; Shain KH
Leuk Lymphoma; 2017 Mar; 58(3):560-568. PubMed ID: 27424609
[TBL] [Abstract][Full Text] [Related]
5. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis.
Saleem K; Franz J; Klem ML; Yabes JG; Boyiadzis M; Jones JR; Shaikh N; Lontos K
Lancet Haematol; 2022 Dec; 9(12):e906-e918. PubMed ID: 36354020
[TBL] [Abstract][Full Text] [Related]
6. Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis.
Giri S; Barth P; Costa LJ; Olszewski AJ
J Geriatr Oncol; 2021 Mar; 12(2):256-261. PubMed ID: 32684352
[TBL] [Abstract][Full Text] [Related]
7. Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.
Liu Y; Hou HA; Qiu H; Tang CH
Sci Rep; 2020 Sep; 10(1):14393. PubMed ID: 32873831
[TBL] [Abstract][Full Text] [Related]
8. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Jones JR; Cairns DA; Gregory WM; Collett C; Pawlyn C; Sigsworth R; Striha A; Henderson R; Kaiser MF; Jenner M; Cook G; Russell NH; Williams C; Pratt G; Kishore B; Lindsay J; Drayson MT; Davies FE; Boyd KD; Owen RG; Jackson GH; Morgan GJ
Blood Cancer J; 2016 Dec; 6(12):e506. PubMed ID: 27935580
[TBL] [Abstract][Full Text] [Related]
9. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.
Engelhardt M; Ihorst G; Landgren O; Pantic M; Reinhardt H; Waldschmidt J; May AM; Schumacher M; Kleber M; Wäsch R
Haematologica; 2015 Oct; 100(10):1340-9. PubMed ID: 26160877
[TBL] [Abstract][Full Text] [Related]
10. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
Jonsdottir G; Björkholm M; Turesson I; Hultcrantz M; Diamond B; Porwit A; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Aug; 107(2):275-282. PubMed ID: 33966293
[TBL] [Abstract][Full Text] [Related]
11. Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs.
Takamatsu H; Matsuda T; Mizuno S; Takahashi T; Fuchida SI; Hanamura I; Kataoka K; Tsukada N; Matsumoto M; Hangaishi A; Doki N; Uchida N; Sawa M; Maruyama Y; Kurahashi S; Nagafuji K; Harazaki Y; Kako S; Iida S; Ichinohe T; Kanda Y; Atsuta Y; Sunami K;
Haematologica; 2023 Dec; 108(12):3399-3408. PubMed ID: 37470160
[TBL] [Abstract][Full Text] [Related]
12. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
[TBL] [Abstract][Full Text] [Related]
13. [Second primary malignancies after the treatment of multiple myeloma].
Makita S; Maruyama D
Nihon Rinsho; 2015 Jan; 73(1):162-6. PubMed ID: 25626323
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.
Sahebi F; Iacobelli S; Sbianchi G; Koster L; Blaise D; Reményi P; Russell NH; Ljungman P; Kobbe G; Apperley J; Trneny M; Krejci M; Wiktor-Jedrzejczak W; Sanchez JF; Schaap N; Isaksson C; Lenhoff S; Browne P; Scheid C; Wilson KMO; Yakoub-Agha I; Muñiz SG; Schönland S; Morris C; Garderet L; Kröger N
Biol Blood Marrow Transplant; 2018 May; 24(5):930-936. PubMed ID: 29339268
[TBL] [Abstract][Full Text] [Related]
15. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
Ragon BK; Shah MV; D'Souza A; Estrada-Merly N; Gowda L; George G; de Lima M; Hashmi S; Kharfan-Dabaja MA; Majhail NS; Banerjee R; Saad A; Hildebrandt GC; Mian H; Abid MB; Battiwalla M; Lekakis LJ; Patel SS; Murthy HS; Nieto Y; Strouse C; Badawy SM; Al Hadidi S; Dholaria B; Aljurf M; Vesole DH; Lee CH; Pawarode A; Gergis U; Miller KC; Holmberg LA; Afrough A; Solh M; Munshi PN; Nishihori T; Anderson LD; Wirk B; Kaur G; Qazilbash MH; Shah N; Kumar SK; Usmani SZ
Blood Adv; 2023 Jun; 7(12):2746-2757. PubMed ID: 36827681
[TBL] [Abstract][Full Text] [Related]
16. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Usmani SZ; Sexton R; Hoering A; Heuck CJ; Nair B; Waheed S; Al Sayed Y; Chauhan N; Ahmad N; Atrash S; Petty N; van Rhee F; Crowley J; Barlogie B
Blood; 2012 Aug; 120(8):1597-600. PubMed ID: 22674807
[TBL] [Abstract][Full Text] [Related]
17. Secondary primary malignancies in patients with multiple myeloma: A single institution experience.
Fei F; Reddy V; Rosenblum F
Hematol Oncol; 2021 Dec; 39(5):674-679. PubMed ID: 34510500
[TBL] [Abstract][Full Text] [Related]
18. Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis.
Mian A; Naqvi SAA; Ayaz A; Husnain M; Aljama MA; Mohyuddin GR; Koehn K; Mohan M; Bin Riaz I; Chakraborty R
Leuk Res; 2023 Aug; 131():107324. PubMed ID: 37285641
[TBL] [Abstract][Full Text] [Related]
19. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
[TBL] [Abstract][Full Text] [Related]
20. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients.
Rosenberg AS; Brunson A; Tuscano J; Jonas BA; Hoeg R; Wun T; Keegan THM
Blood Cancer J; 2021 Jan; 11(1):5. PubMed ID: 33414400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
